Coumadin, the popular but troublesome blood thinner, may soon have to make way for a new drug that seems to work more predictably and safely. Patients will have researchers to thank, along with a not-quite-usual suspect: the cobra.The drug, derived from cobra venom, is expected to reach pharmacies within 18 months under the brand name Exanta. Its manufacturer announced last week it has submitted the drug to the U.S. Food and Drug Administration (FDA) for approval.
